Tuvusertib for astrocytoma with ATRX mutation
Treatments studied
Part of Cancer clinical trials.
This trial tests an oral drug called tuvusertib for people with a specific type of astrocytoma (a brain tumor) that has an ATRX mutation. The goal is to see if the drug can help when the tumor has gotten worse after standard treatments like radiation and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a grade 2, 3, or 4 astrocytoma (a type of brain tumor) that has an IDH mutation and an ATRX mutation.
- Your tumor has grown or come back after standard treatment with radiation and chemotherapy (such as temozolomide or PCV).
- You must be able to take pills by mouth.
- Your blood counts, liver, and kidney function must be good enough (tests will be done to check).
- You have not had more than one prior treatment for your astrocytoma, and you have not received bevacizumab or drugs like tuvusertib before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
This trial tests whether taking vorasidenib after standard radiation and chemotherapy can help prevent low-grade IDH-mutant astrocytoma from growing back. It is for people who have completed first-line therapy and whose tumors have not progressed.
This early-stage study tests ASTX727 in adults with IDH-mutant gliomas that are coming back or progressing. It aims to see whether the medicine can slow the tumor and understand how it works in the body and tumor tissue.
Hear when a new Astrocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.